PL3097189T3 - Chimeryczne białka podobne do alkalicznej fosfatazy - Google Patents

Chimeryczne białka podobne do alkalicznej fosfatazy

Info

Publication number
PL3097189T3
PL3097189T3 PL15703642T PL15703642T PL3097189T3 PL 3097189 T3 PL3097189 T3 PL 3097189T3 PL 15703642 T PL15703642 T PL 15703642T PL 15703642 T PL15703642 T PL 15703642T PL 3097189 T3 PL3097189 T3 PL 3097189T3
Authority
PL
Poland
Prior art keywords
alkaline phosphatase
chimeric proteins
proteins similar
similar
chimeric
Prior art date
Application number
PL15703642T
Other languages
English (en)
Inventor
Willem Raaben
Luigi Johannes Cornelius Jonk
Andrea Van Elsas
Erik Jan VAN DEN BERG
José Luis MILLÁN
Original Assignee
Am-Pharma B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Am-Pharma B.V. filed Critical Am-Pharma B.V.
Publication of PL3097189T3 publication Critical patent/PL3097189T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/03Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001Alkaline phosphatase (3.1.3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
PL15703642T 2014-01-24 2015-01-26 Chimeryczne białka podobne do alkalicznej fosfatazy PL3097189T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14152526 2014-01-24
EP14188158 2014-10-08
EP15703642.7A EP3097189B1 (en) 2014-01-24 2015-01-26 Chimeric alkaline phosphatase-like proteins
PCT/NL2015/050048 WO2015112017A1 (en) 2014-01-24 2015-01-26 Chimeric alkaline phosphatase-like proteins

Publications (1)

Publication Number Publication Date
PL3097189T3 true PL3097189T3 (pl) 2018-11-30

Family

ID=52464544

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15703642T PL3097189T3 (pl) 2014-01-24 2015-01-26 Chimeryczne białka podobne do alkalicznej fosfatazy

Country Status (22)

Country Link
US (4) US9926544B2 (pl)
EP (2) EP3097189B1 (pl)
JP (3) JP6940949B2 (pl)
KR (1) KR102166110B1 (pl)
CN (2) CN106164262B (pl)
AU (1) AU2015209783B2 (pl)
BR (1) BR112016017041B1 (pl)
CA (1) CA2937328C (pl)
DK (1) DK3097189T3 (pl)
ES (1) ES2684639T3 (pl)
HU (1) HUE039784T2 (pl)
IL (1) IL246898B (pl)
MX (1) MX369041B (pl)
PE (1) PE20161442A1 (pl)
PH (1) PH12016501441B1 (pl)
PL (1) PL3097189T3 (pl)
RU (1) RU2683635C2 (pl)
SA (1) SA516371532B1 (pl)
SG (1) SG11201606060WA (pl)
SI (1) SI3097189T1 (pl)
WO (1) WO2015112017A1 (pl)
ZA (1) ZA201605028B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106164262B (zh) 2014-01-24 2020-08-07 安-法玛公司 嵌合型碱性磷酸酶样蛋白
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
MX389350B (es) 2014-12-05 2025-03-19 Alexion Pharma Inc Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones.
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
KR102644116B1 (ko) * 2015-08-17 2024-03-05 알렉시온 파마슈티칼스, 인코포레이티드 알칼린 포스파타제의 제조
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ, インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
CA3019726A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
EP3464573A4 (en) 2016-06-06 2020-02-19 Alexion Pharmaceuticals, Inc. EFFECTS OF METALS ON THE PRODUCTION OF ALKALINE PHOSPHATASES
EP3345614A1 (en) * 2017-01-05 2018-07-11 Amrif B.V. Composition comprising alkaline phosphatase for use in the treatment of arthritides
JP2020512363A (ja) * 2017-03-31 2020-04-23 アレクシオン ファーマシューティカルズ, インコーポレイテッド 成人及び青年における低ホスファターゼ症(hpp)を治療する方法
EP3737750B1 (en) 2018-01-09 2024-06-05 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
US12178857B2 (en) 2018-03-08 2024-12-31 Am-Pharma B.V. Recombinant alkaline phosphatase for use in treating sepsis-associated acute kidney injury
US11638699B2 (en) 2018-03-20 2023-05-02 Theriva Biologics, Inc. Intestinal alkaline phosphatase formulations
WO2019183209A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
CN110499284A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Wnt信号通路激活剂在制备治疗基因ALPL敲除小鼠牙硬组织矿化异常产品中的应用
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
KR20220005560A (ko) 2019-05-06 2022-01-13 신세틱 바이오로직스, 인코퍼레이티드 알칼리성 포스페이트-기반 종양학 치료제
JP2023504208A (ja) 2019-12-09 2023-02-01 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルカリホスファターゼポリペプチド及びその使用方法
US12478662B2 (en) * 2020-01-03 2025-11-25 The United States of America as represented by the Secretary Department of Heath and Human Services TNAP locally administered for promoting periodontal health
CN111110835A (zh) * 2020-01-22 2020-05-08 李鑫荣 一种肠碱性磷酸酶的新应用及其制剂的细胞活性检测方法
CA3190684A1 (en) 2020-09-09 2022-03-17 Jeroen Elassaiss-Schaap Recombinant alkaline phosphatase for use in treating acute respiratory distress syndrome
US12083169B2 (en) 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
CN118580341B (zh) * 2024-06-24 2025-03-18 浙江大学 一种寄生线虫spi-i8蛋白及其在防治炎症疾病中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8328918D0 (en) 1983-10-28 1983-11-30 Unilever Plc Alkaline phosphatase
DE69127482T2 (de) 1990-02-07 1998-03-19 Abbott Lab Alkalische Phosphatase mit verbesserter spezifischer Aktivität zur Verwendung in Indikatorreagenzien
CA2102294A1 (en) 1992-03-10 1993-09-11 Jose L. Millan Recombinant calf intestinal alkaline phosphatase
JPH06284885A (ja) * 1993-04-02 1994-10-11 Tosoh Corp 組換えヒト小腸アルカリフォスファタ−ゼ
EP0701441A1 (en) 1993-06-01 1996-03-20 Cortex Pharmaceuticals, Inc. Alkaline and acid phosphatase inhibitors in treatment of neurological disorders
AU4835693A (en) 1993-08-13 1995-03-14 Rijksuniversiteit Te Groningen Pharmaceutical composition comprising phosphatase or a derivative thereof
EP0732933B1 (en) 1993-11-15 2002-10-09 Celtrix Pharmaceuticals, Inc. Use of igf-1 and igfbp-3 in the manufacture of a medicament for treating a renal disorder
AU6107496A (en) 1995-06-06 1996-12-24 Gensci Regeneration Laboratories, Inc. Modified osteogenic materials
FR2736065B1 (fr) 1995-06-29 1997-09-19 Commissariat Energie Atomique Phosphatases alcalines bacteriennes modifiees et leurs applications.
JP3488327B2 (ja) 1995-12-21 2004-01-19 よつ葉乳業株式会社 牛乳脂肪球膜含有画分の製造法
US20020114802A1 (en) 1998-02-10 2002-08-22 Tjellstrom Bo Arthur Einar Oral immunoglobulin treatment for inflammatory bowel disease
DE19819962A1 (de) 1998-05-05 1999-11-11 Roche Diagnostics Gmbh Hochaktive alkalische Phosphatase
EP1141717A1 (en) 1998-12-21 2001-10-10 Stichting voor de Technische Wetenschappen Diagnosis of sepsis using the lps-binding moiety of alkaline phosphatase
JP2000350596A (ja) 1999-06-11 2000-12-19 Toyobo Co Ltd 分泌性アルカリフォスファターゼの選択的活性測定方法
DE60120007T2 (de) 2000-01-31 2006-11-16 Pfizer Products Inc., Groton Verwendung von Aktivatoren des Prostaglandinrezeptores 4 zur Behandlung von akuter oder chronischer Niereninsuffizienz
WO2002006214A1 (en) 2000-07-19 2002-01-24 Mitsubishi Pharma Corporation Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
DE10101793A1 (de) 2001-01-17 2002-08-01 Manfred Nilius Verwendung von SLPI zur Behandlung chronisch-entzündlicher Darmerkrankungen
WO2002057430A2 (en) 2001-01-20 2002-07-25 Cardion Ag Pluripotent adult stem cells derived from regenerative tissue
JP4238726B2 (ja) 2001-06-01 2009-03-18 味の素株式会社 腸疾患用の薬剤
US7157260B2 (en) 2001-07-26 2007-01-02 Japan Science & Technology Agency Nicotianamine synthase and gene encoding the same
JP4169966B2 (ja) 2001-11-14 2008-10-22 株式会社ヤクルト本社 炎症性腸疾患予防治療剤
CN1425766A (zh) 2001-12-19 2003-06-25 复旦大学 一种多肽——人含碱性磷酸酶活性位点的蛋白-9.24和编码这种多肽的多核苷酸
CA2503621A1 (en) * 2002-11-13 2004-05-27 Genentech, Inc. Methods and compositions for diagnosing dysplasia
US7048914B2 (en) 2002-12-12 2006-05-23 Zoltan Laboratories Placental alkaline phosphatase to control diabetes
AU2003295264A1 (en) * 2002-12-23 2004-07-14 Rijksuniversiteit Groningen Modulation of the thioredoxin pathway
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
JP4305071B2 (ja) 2003-06-30 2009-07-29 株式会社ニコン 信号補正方法
JP2005065564A (ja) 2003-08-22 2005-03-17 Hiroshi Ueda センサー蛋白質
US7157261B2 (en) 2003-10-27 2007-01-02 Canji, Inc. Rat secreted embryonic alkaline phosphatase
US20110142817A1 (en) 2004-02-04 2011-06-16 Pharmaaware Sepsis B.V. Means and method for treating and/or preventing necrotizing enterocolitis
CA2847517A1 (en) 2004-02-04 2005-08-18 Pharmaaware Sepsis B.V. Use of alkaline phosphatase for the detoxification of lps present at mucosal barriers
US8119385B2 (en) 2005-03-04 2012-02-21 Bp Corporation North America Inc. Nucleic acids and proteins and methods for making and using them
US20070059300A1 (en) 2005-09-12 2007-03-15 Zoltan Laboratories Llc Compounds and compositions to control abnormal cell growth
US7695714B2 (en) 2005-12-28 2010-04-13 Zoltan Laboratories Llc Use of alkaline phosphatase to maintain healthy tissue mass in mammals
RU2006103770A (ru) * 2006-02-08 2007-08-20 Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) (Ru) Высокоактивная бактериальная щелочная фосфатаза и фрагмент днк, кодирующий щелочную фосфатазу
US20070280922A1 (en) 2006-06-06 2007-12-06 Zoltan Kiss Consulting Combinations of human proteins to enhance viability of stem cells and progenitor cells
US7718170B2 (en) 2006-08-21 2010-05-18 Essential Skincare, Llc Alkaline phosphatase compositions to reduce skin cancer
EP1952823A1 (en) 2007-01-30 2008-08-06 AM-Pharma B.V. The use of alkaline phosphatase in the treatment of reduced renal function
WO2008104199A1 (en) 2007-03-01 2008-09-04 Gelato Corporation N.V. Use of ecto-phosphatases for the treatment of (acute) myocardial infarction
EP1985697A1 (en) 2007-04-27 2008-10-29 AM-Pharma B.V. Modified phosphatases
PT2662448T (pt) * 2007-05-11 2017-03-29 Alexion Pharma Inc Fosfatase alcalina dirigida ao osso, kits e métodos para a utilização da mesma
EP2030980A1 (en) 2007-08-28 2009-03-04 AM-Pharma B.V. Mutants of lactoferrin
ES2421717T3 (es) 2008-02-29 2013-09-05 Alloksys Life Science B V Fosfatasa alcalina para aumentar la actividad del sistema inmune en un mamífero con riesgo de enfermedades inflamatorias
JP2011521916A (ja) 2008-05-19 2011-07-28 バーナム インスティテュート フォー メディカル リサーチ 腸アルカリホスファターゼモジュレーターおよびそれの使用
WO2010025267A2 (en) 2008-08-29 2010-03-04 The General Hospital Corporation Methods of modulating gastrointestinal tract flora levels with alkaline phosphatase
BR112012027765A2 (pt) * 2010-04-30 2019-09-24 Enobia Pharma Inc métodos, composições e kits para tratamento de distúrbios de mineralização da matriz.
WO2012169892A2 (en) 2011-06-08 2012-12-13 Am-Pharma B.V. The use of alkaline phosphatase for preserving renal function
PT3461891T (pt) 2014-01-24 2020-07-30 Am Pharma Bv Processamento a jusante de uma fosfatase alcalina
CN106164262B (zh) 2014-01-24 2020-08-07 安-法玛公司 嵌合型碱性磷酸酶样蛋白

Also Published As

Publication number Publication date
SA516371532B1 (ar) 2019-02-11
JP7408734B2 (ja) 2024-01-05
EP3097189B1 (en) 2018-07-11
AU2015209783B2 (en) 2020-10-01
US10822597B2 (en) 2020-11-03
PE20161442A1 (es) 2017-01-12
MX2016009625A (es) 2017-05-01
US20190024062A1 (en) 2019-01-24
CA2937328C (en) 2022-09-27
CN106164262B (zh) 2020-08-07
US20210163905A1 (en) 2021-06-03
US9926544B2 (en) 2018-03-27
SG11201606060WA (en) 2016-08-30
JP2022160503A (ja) 2022-10-19
WO2015112017A1 (en) 2015-07-30
RU2016131879A (ru) 2018-03-01
AU2015209783A1 (en) 2016-08-04
JP2020058375A (ja) 2020-04-16
EP3097189A1 (en) 2016-11-30
DK3097189T3 (en) 2018-09-03
IL246898A0 (en) 2016-09-29
KR102166110B1 (ko) 2020-10-16
JP6940949B2 (ja) 2021-09-29
ES2684639T3 (es) 2018-10-03
HUE039784T2 (hu) 2019-02-28
PH12016501441A1 (en) 2016-08-22
SI3097189T1 (sl) 2018-10-30
US11746340B2 (en) 2023-09-05
CA2937328A1 (en) 2015-07-30
US20240174994A1 (en) 2024-05-30
EP3425048A1 (en) 2019-01-09
MX369041B (es) 2019-10-25
KR20160117487A (ko) 2016-10-10
RU2016131879A3 (pl) 2018-08-16
PH12016501441B1 (en) 2023-02-22
NZ722253A (en) 2021-11-26
IL246898B (en) 2019-09-26
JP2017505128A (ja) 2017-02-16
US20170009216A1 (en) 2017-01-12
RU2683635C2 (ru) 2019-03-29
CN106164262A (zh) 2016-11-23
BR112016017041A2 (pt) 2017-10-03
CN111778228A (zh) 2020-10-16
BR112016017041B1 (pt) 2023-09-26
ZA201605028B (en) 2020-02-26

Similar Documents

Publication Publication Date Title
IL286393A (en) Smart connection interface
PL3097189T3 (pl) Chimeryczne białka podobne do alkalicznej fosfatazy
DK3197453T3 (da) Kimært protein
DK3180363T3 (da) Sirp-alpha-immunoglobulin fusionsproteiner
DK3137587T3 (da) Detergentsammensætning
PT3101032T (pt) Onjugado de anticorpo anti-her2-fármaco
DE112015001474A5 (de) Doppelkupplung
DK3164414T3 (da) Antistoffer for IL-15
DK3107562T3 (da) P97-ids-fusionsproteiner
PL3234071T3 (pl) Piec
IL291164A (en) Anti-nme antibody
DK3237432T3 (da) Proteinfremstilling
DE112015001577A5 (de) Doppelkupplung
DK3702450T3 (da) Protein
DE112015003929A5 (de) Doppelkupplung
DK3154689T3 (da) Komplekser
HUE047455T2 (hu) HPA-1A elleni antitestek
LT3178931T (lt) Anti-orai1 antikūnas
HRP20182029T1 (hr) Uti-fuzijski proteini
LT3628731T (lt) Naujas antipresepsino antikūnas
DK3099793T3 (da) Protein
DK3154945T3 (da) Komplekser
DK3126521T3 (da) HNF4G-RSPO2-fusionsgen
HUE047581T2 (hu) Készítmény
DE102014210430A8 (de) Reinigungsgerät